COMBINATION THERAPY IS NOT ASSOCIATED WITH IMPROVED RATES OF CLINICAL OR ENDOSCOPIC REMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH USTEKINUMAB OR VEDOLIZUMAB
Angus W. Jeffrey 1
Sherman Picardo 1
Shankar Menon 1
Kenji So 1
Kannan Venugopal 1
1 Royal Perth Hospital, Perth, Australia
Session
IBD (Posters)
Conference
UEG Week 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]